LTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%

MT Newswires Live

03/05

LTR Pharma (ASX:LTP) has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.

The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.

The initial phase two results are expected in the second quarter, the filing added.

The company's shares rose around 7% in recent Thursday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2617598609"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617598609\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617598609?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617598609","market":"sg","top_or_hot":-1,"title":"LTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%","media":"MT Newswires Live","content":"<html><body><p> LTR Pharma (ASX:LTP) has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.</p><p>The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.</p><p>The initial phase two results are expected in the second quarter, the filing added.</p><p>The company's shares rose around 7% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-05 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LTR Pharma (ASX:LTP) has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.</p><p>The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.</p><p>The initial phase two results are expected in the second quarter, the filing added.</p><p>The company's shares rose around 7% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2617598609","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617598609","pubTimestamp":1772669667,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LTR Pharma  has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.The initial phase two results are expected in the second quarter, the filing added.The company's shares rose around 7% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","LTP.AU":"LTR PHARMA LTD"},"translate_title":"LTR Pharma完成Spontan二期研究的招募；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTP.AU":1},"content_text":"LTR Pharma (ASX:LTP) has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.The initial phase two results are expected in the second quarter, the filing added.The company's shares rose around 7% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}